Hepatitis Research Today is a free monthly online journal that collates and summarizes the latest research about Hepatitis, including details on hepatitis a, b, c, causes, symptoms.

Volume 1 (2006), Issue 9 (September)

1. Frequency and comparative analysis of hapatitis D in petients seeking treatment for hepatitis B.
   J Coll Physicians Surg Pak, 16(9): 581-4. [Abstract] [Full-text]
2. Nanoencapsulation of usnic acid: An attempt to improve antitumour activity and reduce hepatotoxicity.
   Eur J Pharm Biopharm, 64(2): 154-60. [Abstract] [Full-text]
3. Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis.
   Cell Metab, 4(3): 185-98. [Abstract] [Full-text]
4. Is the slippery slope from steatosis to steatohepatitis paved with triglyceride or cholesterol?
   Cell Metab, 4(3): 179-81. [Abstract] [Full-text]
5. CD4+ immune escape and subsequent T-cell failure following chimpanzee immunization against hepatitis C virus.
   Hepatology, 44(3): 736-45. [Abstract] [Full-text]
6. Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: relation to treatment response.
   Hepatology, 44(3): 721-7. [Abstract] [Full-text]
7. Evolution of multi-drug resistant hepatitis B virus during sequential therapy.
   Hepatology, 44(3): 703-12. [Abstract] [Full-text]
8. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up.
   Hepatology, 44(3): 728-35. [Abstract] [Full-text]
9. Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients.
   Hepatology, 44(3): 694-702. [Abstract] [Full-text]
10. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B.
    Hepatology, 44(3): 675-84. [Abstract] [Full-text]
11. Hepatitis C virus entry: molecular biology and clinical implications.
    Hepatology, 44(3): 527-35. [Abstract] [Full-text]
12. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta.
    Hepatology, 44(3): 713-20. [Abstract] [Full-text]
13. pH-independent entry and sequential endosomal sorting are major determinants of hepadnaviral infection in primary hepatocytes.
    Hepatology, 44(3): 685-93. [Abstract] [Full-text]
14. Probable intrafamilial transmission of coxsackievirus b3 with vertical transmission, severe early-onset neonatal hepatitis, and prolonged viral RNA shedding.
    Pediatrics, 118(3): e929-33. [Abstract] [Full-text]
15. Estimation of dynamical model parameters taking into account undetectable marker values.
    BMC Med Res Methodol, 6: 38. [Abstract] [Full-text]
16. Arbidol: a broad-spectrum antiviral that inhibits acute and chronic HCV infection.
    Virol J, 3: 56. [Abstract] [Full-text]
17. Rapid quantitation of lamivudine-resistant mutants in lamivudine treated and untreated patients with chronic hepatitis B virus infection.
    Clin Chim Acta, 373(1): 172-5. [Abstract] [Full-text]
18. Pulmonary alterations in patients with chronic HCV infection.
    Dig Liver Dis, 38(9): 673-6. [Abstract] [Full-text]
19. Hepatocarcinogenesis in viral Hepatitis B infection: the role of HBx and p53.
    Acta Med Indones, 38(3): 154-9. [Abstract] [Full-text]
20. Functional analysis of complex hepatitis B virus variants associated with development of liver cirrhosis.
    Gastroenterology, 131(3): 765-80. [Abstract] [Full-text]
21. Hemophilic siblings with chronic hepatitis C: Familial aggregation of spontaneous and treatment-related viral clearance.
    Gastroenterology, 131(3): 757-64. [Abstract] [Full-text]
22. Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: a randomized phase II trial.
    J Hepatol, 45(4): 539-46. [Abstract] [Full-text]
23. Quantification of hepatitis B virus covalently closed circular DNA in patients with hepatocellular carcinoma.
    J Hepatol, 45(4): 553-9. [Abstract] [Full-text]
24. Transmission of hepatitis C virus by blood transfusions and other medical procedures: a global review.
    J Hepatol, 45(4): 607-16. [Abstract] [Full-text]
25. Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral centre.
    J Hepatol, 45(4): 575-83. [Abstract] [Full-text]
26. Cultivation of HepG2.2.15 on Cytodex-3: higher yield of hepatitis B virus and less subviral particles compared to conventional culture methods.
    J Hepatol, 45(4): 547-52. [Abstract] [Full-text]
27. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide.
    J Hepatol, 45(4): 529-38. [Abstract] [Full-text]
28. Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis.
    J Hepatol, 45(4): 584-91. [Abstract] [Full-text]
29. Toll-like receptor expression in chronic hepatitis C: correlation with pro-inflammatory cytokine levels and liver injury.
    Inflamm Res, 55(7): 279-85. [Abstract] [Full-text]
30. Azathioprine monotherapy for maintenance of remission in pediatric patients with autoimmune hepatitis.
    J Pediatr Gastroenterol Nutr, 43(3): 353-6. [Abstract] [Full-text]
31. Relationship between viral load and genotypes of hepatitis B virus in children with chronic hepatitis B.
    J Pediatr Gastroenterol Nutr, 43(3): 342-7. [Abstract] [Full-text]
32. Identification of genotype 1 hepatitis E virus in samples from swine in Cambodia.
    J Clin Microbiol, 44(9): 3440-2. [Abstract] [Full-text]
33. Quantitative assessment of serum NV-F virus DNA concentrations in samples from patients coinfected with hepatitis B or C virus.
    J Clin Microbiol, 44(9): 3130-3. [Abstract] [Full-text]
34. Quantitative trait loci analysis of mice administered the methionine-choline deficient dietary model of experimental steatohepatitis.
    Liver Int, 26(8): 1000-5. [Abstract] [Full-text]
35. IFNgamma expression inhibits LHBs storage disease and ground glass hepatocyte appearance, but exacerbates inflammation and apoptosis in HBV surface protein-accumulating transgenic livers.
    Liver Int, 26(8): 986-93. [Abstract] [Full-text]
36. Useful parameters for distinguishing nonalcoholic steatohepatitis with mild steatosis from cryptogenic chronic hepatitis in the Japanese population.
    Liver Int, 26(8): 956-63. [Abstract] [Full-text]
37. Viral factors correlate with hepatitis B e antigen seroconverson in patients with chronic hepatitis B.
    Liver Int, 26(8): 949-55. [Abstract] [Full-text]
38. Role of neutrophils in acute inflammatory liver injury.
    Liver Int, 26(8): 912-9. [Abstract] [Full-text]
39. Alcohol consumption within the context of hepatitis C: a qualitative study of non-problematic drinkers.
    Alcohol Alcohol, 41(5): 546-52. [Abstract] [Full-text]
40. Outbreak of hepatitis B in a nursing home associated with capillary blood sampling.
    Epidemiol Infect, 134(5): 1102-13. [Abstract] [Full-text]
41. Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection.
    J Infect Dis, 194(7): 895-903. [Abstract] [Full-text]
42. 2'-,5'-Oligoadenylate synthetase response ratio predicting virological response to PEG-interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C.
    J Clin Pharm Ther, 31(5): 441-6. [Abstract] [Full-text]
43. Prevalence of septic events, type 1 hepatorenal syndrome, and mortality in severe alcoholic hepatitis and utility of discriminant function and MELD score in predicting these adverse events.
    Dig Dis Sci, 51(9): 1637-43. [Abstract] [Full-text]
44. From trials to a real hospital setting: effectiveness of pegylated interferon-alpha-2b/ribavirin combination therapy for naïve chronic hepatitis C patients.
    Dig Dis Sci, 51(9): 1619-26. [Abstract] [Full-text]
45. Association between ABO blood group and fibrosis severity in chronic hepatitis C infection.
    Dig Dis Sci, 51(9): 1633-6. [Abstract] [Full-text]
46. Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study.
    Lancet, 368(9539): 938-45. [Abstract] [Full-text]
47. Hepatitis B virus immunization with an adjuvant containing vaccine after liver transplantation for hepatitis B-related disease: failure of humoral and cellular immune response.
    Transpl Int, 19(10): 828-33. [Abstract] [Full-text]
48. Interferon-induced depression in chronic hepatitis C.
    J Antimicrob Chemother, 58(4): 711-3. [Abstract] [Full-text]
49. Short-term treatment duration for HCV-2 and HCV-3 infected patients.
    Dig Liver Dis, 38(10): 741-8. [Abstract] [Full-text]
50. Extended double-dosage HBV vaccination after liver transplantation is ineffective, in the absence of lamivudine and prior wash-out of human Hepatitis B immunoglobulins.
    Dig Liver Dis, 38(10): 749-54. [Abstract] [Full-text]
51. Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention.
    Clin Gastroenterol Hepatol, 4(9): 1076-81. [Abstract] [Full-text]
52. Chronic hepatitis B viral infection independently predicts renal outcome in type 2 diabetic patients.
    Diabetologia, 49(8): 1777-84. [Abstract] [Full-text]
53. The sulfone syndrome secondary to dapsone prophylaxis in a patient undergoing unrelated hematopoietic stem cell transplantation.
    Hematol Oncol, 24(3): 164-5. [Abstract] [Full-text]
54. A prospective study on chemotherapy-induced hepatitis B virus reactivation in chronic HBs Ag carriers with hematologic malignancies and pre-emptive therapy with nucleoside analogues.
    Leuk Lymphoma, 47(8): 1608-12. [Abstract] [Full-text]
55. Acute sporadic hepatitis E in children: diagnostic relevance of specific immunoglobulin M and immunoglobulin G compared with nested reverse transcriptase PCR.
    FEMS Immunol Med Microbiol, 48(1): 16-20. [Abstract] [Full-text]
56. Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy.
    Ann Oncol, 17(9): 1434-40. [Abstract] [Full-text]
57. Systemic inflammation and remote organ damage following bilateral femur fracture requires Toll-like receptor 4.
    Am J Physiol Regul Integr Comp Physiol, 291(4): R970-6. [Abstract] [Full-text]
58. Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis.
    Am J Gastroenterol, 101(9): 2076-89. [Abstract] [Full-text]
59. Characterization of CD4, CD8, CD56 positive lymphocytes and C4d deposits to distinguish acute cellular rejection from recurrent hepatitis C in post-liver transplant biopsies.
    Clin Transplant, 20(5): 624-33. [Abstract] [Full-text]
60. Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia.
    Addiction, 101(10): 1499-508. [Abstract] [Full-text]
61. Differences in access to care among injection drug users infected either with HIV and hepatitis C or hepatitis C alone.
    AIDS Care, 18(7): 690-3. [Abstract] [Full-text]
62. Management of hepatitis C in the setting of liver transplantation.
    Clin Liver Dis, 10(2): 321-37, ix. [Abstract] [Full-text]
63. Hepatitis C Virus in the HIV-infected patient.
    Clin Liver Dis, 10(2): 303-20, viii. [Abstract] [Full-text]
64. Management of drug-resistant chronic hepatitis B.
    Clin Liver Dis, 10(2): 275-302, viii. [Abstract] [Full-text]
65. Alcoholic hepatitis.
    Clin Liver Dis, 10(2): 219-37, vii. [Abstract] [Full-text]
66. Seroprevalence of hepatitis B and hepatitis C in patients with thalassemia and sickle cell anemia in a long-term follow-up.
    Arch Med Res, 37(7): 895-8. [Abstract] [Full-text]
67. Involvement of innate immunity in the pathogenesis of chronic hepatitis C in children.
    Scand J Immunol, 64(4): 425-32. [Abstract] [Full-text]
68. Transient immunological control during acute hepatitis C virus infection: ex vivo analysis of helper T-cell responses.
    J Viral Hepat, 13(10): 708-14. [Abstract] [Full-text]
69. Accurate model predicting sustained response at week 4 of therapy with pegylated interferon with ribavirin in patients with chronic hepatitis C.
    J Viral Hepat, 13(10): 701-7. [Abstract] [Full-text]
70. Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons.
    J Viral Hepat, 13(10): 683-9. [Abstract] [Full-text]
71. Treatment of hepatitis C virus and human immunodeficiency virus coinfection: from large trials to real life.
    J Viral Hepat, 13(10): 678-82. [Abstract] [Full-text]
72. Predictive value of serum globulin levels for the extent of hepatic fibrosis in patients with chronic hepatitis B infection.
    J Viral Hepat, 13(10): 671-7. [Abstract] [Full-text]
73. Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies.
    J Viral Hepat, 13(10): 659-70. [Abstract] [Full-text]
74. Diagnostic accuracy of a fibrosis serum panel (FIBROSpect II) compared with Knodell and Ishak liver biopsy scores in chronic hepatitis C patients.
    J Viral Hepat, 13(10): 652-8. [Abstract] [Full-text]
75. Longitudinal evaluation of a fibrosis index combining MMP-1 and PIIINP compared with MMP-9, TIMP-1 and hyaluronic acid in patients with chronic hepatitis C treated by interferon-alpha and ribavirin.
    J Viral Hepat, 13(10): 643-51. [Abstract] [Full-text]
76. Hepatitis C recurrence after liver transplantation: Viral and histologic response to full-dose PEG-interferon and ribavirin.
    Am J Transplant, 6(10): 2348-55. [Abstract] [Full-text]
77. Emerging issues in hepatitis C virus-positive liver and kidney transplant recipients.
    Am J Transplant, 6(10): 2232-7. [Abstract] [Full-text]
78. Successful treatment of hepatitis B virus infection with Lamivudine after heart transplantation.
    Transplant Proc, 38(7): 2138-40. [Abstract] [Full-text]
79. Outcomes of hepatitis B virus recurrence after liver transplantation.
    Transplant Proc, 38(7): 2123-4. [Abstract] [Full-text]
80. Ganciclovir and the treatment of Epstein-Barr virus hepatitis.
    J Gastroenterol Hepatol, 21(11): 1758-60. [Abstract] [Full-text]
81. Randomized, double-blind, placebo-controlled trial of bovine lactoferrin in patients with chronic hepatitis C.
    Cancer Sci, 97(10): 1105-10. [Abstract] [Full-text]
82. Hepatitis B virus RNA is measurable in serum and can be a new marker for monitoring lamivudine therapy.
    J Gastroenterol, 41(8): 785-90. [Abstract] [Full-text]
83. Dynamics of immature subsets of dendritic cells during antiviral therapy in HLA-A24-positive chronic hepatitis C patients.
    J Gastroenterol, 41(8): 758-64. [Abstract] [Full-text]
84. Hepatitis B risks and immunization coverage among American travelers.
    J Travel Med, 13(5): 273-80. [Abstract] [Full-text]
85. Concentrations of soluble Fas and soluble Fas ligand as indicators of programmed cell death among patients coinfected with Human Immunodeficiency Virus and Hepatitis C Virus.
    Viral Immunol, 19(3): 570-5. [Abstract] [Full-text]
86. Predictors for hematopoietic growth factors use in HIV/HCV-coinfected patients treated with peginterferon alfa 2b and ribavirin.
    AIDS Patient Care STDS, 20(9): 612-9. [Abstract] [Full-text]
87. Phenotypic and functional status of intrahepatic T cells in chronic hepatitis C.
    J Infect Dis, 194(8): 1068-77. [Abstract] [Full-text]
88. In vitro interaction between hepatitis C virus (HCV) envelope glycoprotein E2 and serum lipoproteins (LPs) results in enhanced cellular binding of both HCV E2 and LPs.
    J Infect Dis, 194(8): 1058-67. [Abstract] [Full-text]
89. Complete genome sequence and phylogenetic analysis of hepatitis B virus (HBV) isolated from Mongolian patients with chronic HBV infection.
    Virus Genes, 33(3): 345-9. [Abstract] [Full-text]
90. The phylogenetic analysis of hepatitis C virus isolates obtained from two Iranian carriers revealed evidence for a new subtype of HCV genotype 3.
    Virus Genes, 33(3): 271-8. [Abstract] [Full-text]
91. Liver steatosis in hepatitis C positive hemodialysis patients and factors affecting IFN-2a treatment.
    Scand J Gastroenterol, 41(10): 1235-41. [Abstract] [Full-text]
92. Virological outcome of chronic hepatitis B virus infection in HIV-coinfected patients receiving anti-HBV active antiretroviral therapy.
    AIDS Res Hum Retroviruses, 22(9): 842-8. [Abstract] [Full-text]
93. Impact of antiretroviral treatment-related toxicities on hospital admissions in HIV-infected patients.
    AIDS Res Hum Retroviruses, 22(9): 825-9. [Abstract] [Full-text]
94. The status of liver transplantation for hepatitis C.
    Expert Opin Biol Ther, 6(10): 993-1002. [Abstract] [Full-text]
95. Risk perceptions and behavioral intentions for Hepatitis B: how do young adults fare?
    Health Educ Res, 21(5): 654-61. [Abstract] [Full-text]
96. The ultrastructural morphology of native hepatitis B virus.
    Med Mol Morphol, 39(3): 136-45. [Abstract] [Full-text]
97. Molecular biology of hepatitis B virus: effect of nucleotide substitutions on the clinical features of chronic hepatitis B.
    Med Mol Morphol, 39(3): 113-20. [Abstract] [Full-text]
98. Effect of nonviral factors on hepatitis C recurrence after liver transplantation.
    Ann Surg, 244(4): 563-71. [Abstract] [Full-text]
99. Epidemiology of hepatitis C virus among long-term dialysis patients: a 9-year study in an Italian region.
    Am J Kidney Dis, 48(4): 629-37. [Abstract] [Full-text]
100. A novel accurate ACRS-PCR method with a digestion internal control for identification of wild type and YMDD mutants of hepatitis B virus strains.
     J Virol Methods, 137(2): 298-303. [Abstract] [Full-text]
101. Comprehensive analysis of differential gene expression profiles on D-galactosamine-induced acute mouse liver injury and regeneration.
     Toxicology, 227(1): 136-44. [Abstract] [Full-text]
102. Detection of memory B lymphocytes specific to hepatitis B virus (HBV) surface antigen (HBsAg) from HBsAg-vaccinated or HBV-immunized subjects by ELISPOT assay.
     J Immunol Methods, 315(1): 144-52. [Abstract] [Full-text]
103. Syncytial giant cell hepatitis in human immunodeficiency virus-infected patients with chronic hepatitis C: 2 cases and review of the literature.
     Hum Pathol, 37(10): 1344-9. [Abstract] [Full-text]
104. Immunosuppression, hepatotoxicity and depression of antioxidant status by arecoline in albino mice.
     Toxicology, 227(1): 94-104. [Abstract] [Full-text]
105. A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C.
     Clin Chem, 52(10): 1887-96. [Abstract] [Full-text]
106. Development and validation of an improved RT-PCR assay with nested universal primers for detection of hepatitis E virus strains with significant sequence divergence.
     J Virol Methods, 137(2): 325-33. [Abstract] [Full-text]
107. Pathophysiological role of the acute inflammatory response during acetaminophen hepatotoxicity.
     Toxicol Appl Pharmacol, 216(1): 98-107. [Abstract] [Full-text]
108. Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis.
     Rheumatology (Oxford), 45(10): 1294-7. [Abstract] [Full-text]
109. RAT CYP3A and CYP2B1/2 were not associated with nevirapine-induced hepatotoxicity.
     Methods Find Exp Clin Pharmacol, 28(7): 423-31. [Abstract] [Full-text]
110. Hepatitis B seroprevalence in Thailand: 12 years after hepatitis B vaccine integration into the national expanded programme on immunization.
     Trop Med Int Health, 11(10): 1496-502. [Abstract] [Full-text]
111. Quantification of hepatitis B virus genomes and infectivity in human serum samples.
     Transfusion, 46(10): 1829-35. [Abstract] [Full-text]
112. Accuracy of hepatitis C virus core antigen testing in pools among seroconverters.
     Transfusion, 46(10): 1822-8. [Abstract] [Full-text]
113. Diversity and origin of hepatitis C virus infection among unpaid blood donors in the Netherlands.
     Transfusion, 46(10): 1719-28. [Abstract] [Full-text]
114. Methylprednisolone-induced toxic hepatitis.
     Ann Pharmacother, 40(10): 1868-71. [Abstract] [Full-text]
115. Molecular epidemiology of human liver cancer: insights into etiology, pathogenesis and prevention from The Gambia, West Africa.
     Carcinogenesis, 27(10): 2070-82. [Abstract] [Full-text]
116. Nonimmune hydrops fetalis and hepatitis in a neonate with congenital human immunodeficiency virus infection.
     Pediatr Infect Dis J, 25(10): 952-4. [Abstract] [Full-text]
117. Detection of HEV antigen as a novel marker for the diagnosis of hepatitis E.
     J Med Virol, 78(11): 1441-8. [Abstract] [Full-text]
118. Characterization of HCV strains in an oncohematological pediatric department reveals little horizontal transmission but multiple introductions by un-screened blood products in the past.
     J Med Virol, 78(11): 1411-22. [Abstract] [Full-text]
119. A natural inter-genotypic (2b/1b) recombinant of hepatitis C virus in the Philippines.
     J Med Virol, 78(11): 1423-8. [Abstract] [Full-text]
120. Co-circulation of genotype IA and new variant IB hepatitis A virus in outbreaks of acute hepatitis in Hungary--2003/2004.
     J Med Virol, 78(11): 1392-7. [Abstract] [Full-text]
121. High prevalence of hepatitis C virus subtypes 4c and 4d in Malaga (Spain): phylogenetic and epidemiological analyses.
     J Med Virol, 78(11): 1429-35. [Abstract] [Full-text]
122. High and persistent excretion of hepatitis A virus in immunocompetent patients.
     J Med Virol, 78(11): 1398-405. [Abstract] [Full-text]
123. Peripheral insulin resistance during treatment of chronic hepatitis C with peguilated interferon plus ribavirin.
     J Med Virol, 78(11): 1406-10. [Abstract] [Full-text]

© 2006-2008 Hepatitis Research Today. All Rights Reserved.